Display options
Cite
Zhang Q, Wang W, Yuan Q, et al. Correlation between immune-related adverse events and the efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: systematic review and meta-analysis. Cancer Chemother Pharmacol. 2021;89(1):1-9doi: 10.1007/s00280-021-04375-2.
Zhang, Q., Wang, W., Yuan, Q., Li, L., Wang, Y. C., Chi, C. Z., & Xu, C. H. (2022). Correlation between immune-related adverse events and the efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: systematic review and meta-analysis. Cancer chemotherapy and pharmacology, 89(1), 1-9. https://doi.org/10.1007/s00280-021-04375-2
Zhang, Qian, et al. "Correlation between immune-related adverse events and the efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: systematic review and meta-analysis." Cancer chemotherapy and pharmacology vol. 89,1 (2022): 1-9. doi: https://doi.org/10.1007/s00280-021-04375-2
Zhang Q, Wang W, Yuan Q, Li L, Wang YC, Chi CZ, Xu CH. Correlation between immune-related adverse events and the efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: systematic review and meta-analysis. Cancer Chemother Pharmacol. 2022 Jan;89(1):1-9. doi: 10.1007/s00280-021-04375-2. Epub 2021 Nov 25. PMID: 34821962.
Copy Download .nbib Format: NLM
Share it on

Cancer Chemother Pharmacol. 2022 Jan;89(1):1-9. doi: 10.1007/s00280-021-04375-2. Epub 2021 Nov 25.

Correlation between immune-related adverse events and the efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: systematic review and meta-analysis.

Cancer chemotherapy and pharmacology

Qian Zhang, Wei Wang, Qi Yuan, Li Li, Yu-Chao Wang, Chuan-Zhen Chi, Chun-Hua Xu

Affiliations

  1. Department of Respiratory Medicine, Nanjing Chest Hospital, 215 Guangzhou Road, Nanjing, 210029, China.
  2. Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, 210029, Jiangsu, China.
  3. Clinical Center of Nanjing Respiratory Diseases and Imaging, Nanjing, 210029, Jiangsu, China.
  4. Department of Respiratory Medicine, Nanjing Chest Hospital, 215 Guangzhou Road, Nanjing, 210029, China. [email protected].
  5. Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, 210029, Jiangsu, China. [email protected].
  6. Clinical Center of Nanjing Respiratory Diseases and Imaging, Nanjing, 210029, Jiangsu, China. [email protected].

PMID: 34821962 DOI: 10.1007/s00280-021-04375-2

Abstract

OBJECTIVE: Anti-programmed cell death-1 and programmed cell death ligand-1 (PD-1/PD-L1) inhibitors have been proved to have a significant clinical efficacy in the treatment of non-small cell lung cancer (NSCLC). Many studies have demonstrated that immune-related adverse events (irAEs) are significantly correlated with clinical efficacy, but the results are not consistent. This meta-analysis aimed to evaluate the associations between irAEs and efficacy.

METHODS: Comprehensive searches were conducted on PubMed and EMBASE database. The HR and 95% CI were used to assess the associations between immune-related adverse events and efficacy of overall survival and progression-free survival. Subgroup analyses were performed based on irAEs type and grade of irAEs. Heterogeneity and publication bias were also assessed by Q test, I

RESULTS: Compared with non-irAEs, the development of irAEs was significantly improved PFS and OS (PFS: HR = 0.55, 95% CI = 0.51-0.60, p < 0.001; OS: HR = 0.74, 95% CI = 0.68-0.81, p < 0.001). In the subgroup analyses, the occurrence of endocrine irAEs, gastrointestinal irAEs, skin lesions and low-grade irAEs was also significantly correlated with the efficacy. Additionally, the association between severe-grade irAEs and survival benefits on PFS was significant, but not on OS.

CONCLUSIONS: The results indicated that the occurrence of irAEs was significantly associated with a better efficacy in the treatment of NSCLC, especially endocrine, gastrointestinal, skin and low-grade irAEs.

© 2021. The Author(s).

Keywords: Efficacy; Immune-related adverse event; Inhibitor; Non-small cell lung cancer; PD-1; PD-L1

References

  1. Mok TSK, Wu YL, Kudaba I et al (2019) Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 393(10183):1819–1830 - PubMed
  2. Vokes EE, Ready N, Felip E et al (2018) Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann Oncol 29(4):959–965 - PubMed
  3. Hellmann MD, Ciuleanu TE, Pluzanski A et al (2018) Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med 378(22):2093–2104 - PubMed
  4. Weber JS, Kahler KC, Hauschild A (2012) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30(21):2691–2697 - PubMed
  5. Brahmer JR, Lacchetti C, Schneider BJ et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol 36(17):1714–1768 - PubMed
  6. Haratani K, Hayashi H, Chiba Y et al (2018) Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol 4(3):374–378 - PubMed
  7. Toi Y, Sugawara S, Kawashima Y et al (2018) Association of immune-related adverse events with clinical benefit in patients with advanced non-small-cell lung cancer treated with nivolumab. Oncologist 23(11):1358–1365 - PubMed
  8. Sanlorenzo M, Vujic I, Daud A et al (2015) Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol 151(11):1206–1212 - PubMed
  9. Zhou X, Yao Z, Yang H et al (2020) Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Med 18(1):87 - PubMed
  10. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22(4):719–748 - PubMed
  11. DerSimonian R, Kacker R (2007) Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 28(2):105–114 - PubMed
  12. Egger M, Davey Smith G, Schneider M et al (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634 - PubMed
  13. Osorio JC, Ni A, Chaft JE et al (2017) Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol 28(3):583–589 - PubMed
  14. Sato K, Akamatsu H, Murakami E et al (2018) Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Lung Cancer 115:71–74 - PubMed
  15. Hughes RT, Black PJ, Page BR et al (2016) Local control of brain metastases after stereotactic radiosurgery: the impact of whole brain radiotherapy and treatment paradigm. J Radiosurg SBRT 4(2):89–96 - PubMed
  16. Lisberg A, Tucker DA, Goldman JW et al (2018) Treatment-related adverse events predict improved clinical outcome in NSCLC patients on Keynote-001 at a single center. Cancer Immunol Res 6(3):288–294 - PubMed
  17. Fujimoto D, Yoshioka H, Kataoka Y et al (2018) Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: a multicenter retrospective cohort study. Lung Cancer 119:14–20 - PubMed
  18. Jacobsen JT, Mesin L, Markoulaki S et al (2018) One-step generation of monoclonal B cell receptor mice capable of isotype switching and somatic hypermutation. J Exp Med 215(10):2686–2695 - PubMed
  19. Lesueur P, Escande A, Thariat J et al (2018) Safety of combined PD-1 pathway inhibition and radiation therapy for non-small-cell lung cancer: a multicentric retrospective study from the GFPC. Cancer Med 7(11):5505–5513 - PubMed
  20. Ksienski D, Wai ES, Croteau N et al (2019) Efficacy of nivolumab and pembrolizumab in patients with advanced non-small-cell lung cancer needing treatment interruption because of adverse events: a retrospective multicenter analysis. Clin Lung Cancer 20(1):e97–e106 - PubMed
  21. Grangeon M, Tomasini P, Chaleat S et al (2019) Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer. Clin Lung Cancer 20(3):201–207 - PubMed
  22. Ricciuti B, Genova C, De Giglio A et al (2019) Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. J Cancer Res Clin Oncol 145(2):479–485 - PubMed
  23. Toi Y, Sugawara S, Sugisaka J et al (2019) Profiling preexisting antibodies in patients treated with Anti-PD-1 therapy for advanced non-small cell lung cancer. JAMA Oncol 5(3):376–383 - PubMed
  24. Cortellini A, Chiari R, Ricciuti B et al (2019) Correlations between the immune-related adverse events spectrum and efficacy of Anti-PD1 immunotherapy in NSCLC patients. Clin Lung Cancer 20(4):237–247 - PubMed
  25. Ahn BC, Pyo KH, Xin CF et al (2019) Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice. J Cancer Res Clin Oncol 145(6):1613–1623 - PubMed
  26. Berner F, Bomze D, Diem S et al (2019) Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer. JAMA Oncol 5(7):1043–1047 - PubMed
  27. Imai H, Wasamoto S, Yamaguchi O et al (2020) Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer. J Cancer Res Clin Oncol 146(2):457–466 - PubMed
  28. Baldini E, Lunghi A, Cortesi E et al (2020) Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: the Italian NSCLC expanded access program. Lung Cancer 140:59–64 - PubMed
  29. Ksienski D, Wai ES, Croteau NS et al (2020) Association of age with differences in immune related adverse events and survival of patients with advanced non small cell lung cancer receiving pembrolizumab or nivolumab. J Geriatr Oncol 11(5):807–813 - PubMed
  30. Sugano T, Seike M, Saito Y et al (2020) Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer. Thorac Cancer 11(4):1052–1060 - PubMed
  31. Naqash AR, Ricciuti B, Owen DH et al (2020) Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort. Cancer Immunol Immunother 69(7):1177–1187 - PubMed
  32. Yamaguchi O, Imai H, Minemura H et al (2020) Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer. Cancer Chemother Pharmacol 85(4):761–771 - PubMed
  33. Cortellini A, Friedlaender A, Banna GL et al (2020) Immune-related adverse events of pembrolizumab in a large real-world cohort of patients with NSCLC With a PD-L1 expression ≥50% and their relationship with clinical outcomes. Clin Lung Cancer 21(6):498–508 - PubMed
  34. Noguchi S, Suminaga K, Kaki T, Kawachi H, Fukao A, Terashita S et al (2020) Correlation of immune-related adverse events and effects of pembrolizumab monotherapy in patients with non-small cell lung cancer. Lung Cancer (Auckl) 11:53–57 - PubMed
  35. Kubo T, Watanabe H, Ninomiya K et al (2020) Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patients. Jpn J Clin Oncol 50(12):1447–1453 - PubMed
  36. Rizvi NA, Hellmann MD, Snyder A, et al. (2015) Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348(6230):124–128 - PubMed
  37. Michot JM, Bigenwald C, Champiat S et al (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54:139–148 - PubMed
  38. Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378(2):158–168 - PubMed
  39. Sibaud V (2018) Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am J Clin Dermatol 19(3):345–361 - PubMed
  40. Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373(17):1627–1639 - PubMed
  41. Reck M, Rodriguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375(19):1823–1833 - PubMed
  42. Aso M, Toi Y, Sugisaka J et al (2020) Association between skin reaction and clinical benefit in patients treated with anti-programmed cell death 1 monotherapy for advanced non-small cell lung cancer. Oncologist 25(3):e536–e544 - PubMed
  43. Wang DY, Salem JE, Cohen JV et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4(12):1721–1728 - PubMed
  44. Rogatsky I, Ivashkiv LB (2006) Glucocorticoid modulation of cytokine signaling. Tissue Antigens 68(1):1–12 - PubMed

Publication Types